Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including lenacapavir—HIV’s ability to evolve resistance to the breakthrough antiviral.

NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum ...

The CDC is no longer recommending that all adolescents and teens get vaccinated for potentially fatal bacterial meningitis, ...

From effective outbreak control to promising new research, a few developments that suggest key parts of the global health system are still functioning well, even under strain. Get the latest in the ...

The announcement of the cuts prompted warnings from around the world about the potential consequences. In the Journal of ...

Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...

The US government paused all foreign assistance in January 2025. This abrupt decision affected the delivery of life-saving HIV medicines and the provision of HIV prevention services to millions of ...

This article originally appeared on Politifact. Over the holidays, U.S. flu cases skyrocketed. Weekly hospitalizations from the virus went from under 7,000 at the start of December to over 33,000 by ...

A recent study published in Engineering has shed light on the transmission and epidemiological trends of tmexCD1-toprJ1-positive Klebsiella pneumoniae across various ecological niches, highlighting ...

Dr Ray O’Connor takes a look at recent clinical articles on the importance of promoting vaccines for Measles, HIV, Gonorrhoea ...

Imagine going to the hospital for a bacterial ear infection and hearing your doctor say, "We're out of options." It may sound ...